Loading...
•
Sep 30, 2021
Allogene Q3 2021 Earnings Report
Allogene Therapeutics reported financial results for Q3 2021 and provided a business update, highlighting ongoing efforts to resolve the FDA clinical hold and advance preclinical programs.
Key Takeaways
Allogene Therapeutics reported a net loss of $78.2 million for the third quarter of 2021. As of September 30, 2021, the company's cash, cash equivalents, and investments totaled $861.7 million. The FDA has placed a hold on the Company’s AlloCAR T clinical trials and the company is working to resolve the hold.
New clinical data from the ALPHA, ALPHA2 and UNIVERSAL AlloCAR T™ trials to be presented at ASH Annual Meeting.
Discussions ongoing as the company seeks to resolve FDA clinical hold.
Ended Q3 with $862 million in cash, cash equivalents and investments.
Abstracts from the ALPHA (poster session) and ALPHA2 (oral session) trials were selected for presentation at the ASH meeting in early December.
Forward Guidance
Allogene continues to expect full year GAAP Operating Expenses to be between $300 and $330 million including estimated non-cash stock-based compensation expense of $80 to $90 million and excluding any impact from potential business development activities.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...